These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34519832)

  • 1. Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: a randomized controlled trial.
    Waltman N; Kupzyk KA; Flores LE; Mack LR; Lappe JM; Bilek LD
    Osteoporos Int; 2022 Feb; 33(2):475-486. PubMed ID: 34519832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
    Waltman NL; Twiss JJ; Ott CD; Gross GJ; Lindsey AM; Moore TE; Berg K; Kupzyk K
    Osteoporos Int; 2010 Aug; 21(8):1361-9. PubMed ID: 19802506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women.
    Bilek LD; Waltman NL; Lappe JM; Kupzyk KA; Mack LR; Cullen DM; Berg K; Langel M; Meisinger M; Portelli-Trinidad A; Lang M
    BMC Womens Health; 2016 Aug; 16(1):59. PubMed ID: 27576310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
    Sestak I; Singh S; Cuzick J; Blake GM; Patel R; Gossiel F; Coleman R; Dowsett M; Forbes JF; Howell A; Eastell R
    Lancet Oncol; 2014 Dec; 15(13):1460-1468. PubMed ID: 25456365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study.
    Leung JY; Ho AY; Ip TP; Lee G; Kung AW
    Bone; 2005 Feb; 36(2):358-64. PubMed ID: 15780963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
    Sebba AI; Bonnick SL; Kagan R; Thompson DE; Skalky CS; Chen E; de Papp AE;
    Curr Med Res Opin; 2004 Dec; 20(12):2031-41. PubMed ID: 15706659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
    Greenspan SL; Brufsky A; Lembersky BC; Bhattacharya R; Vujevich KT; Perera S; Sereika SM; Vogel VG
    J Clin Oncol; 2008 Jun; 26(16):2644-52. PubMed ID: 18427147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
    Dundar U; Kavuncu V; Ciftci IH; Evcik D; Solak O; Cakir T
    J Bone Miner Metab; 2009; 27(4):464-70. PubMed ID: 19301089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
    Mok CC; Tong KH; To CH; Siu YP; Ma KM
    Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis.
    Li Y; Zhang Z; Deng X; Chen L
    J Huazhong Univ Sci Technolog Med Sci; 2005; 25(5):527-9. PubMed ID: 16463664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
    Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve-month resistance and impact exercise program or risedronate provides a relative benefit to hip bone structure in postmenopausal women: results from a randomized controlled trial.
    Blay R; Flores LE; Kupzyk K; Waltman N; Lappe J; Mack L; Bilek L
    Osteoporos Int; 2024 May; 35(5):877-891. PubMed ID: 38368307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.
    Greenspan SL; Vujevich KT; Brufsky A; Lembersky BC; van Londen GJ; Jankowitz RC; Puhalla SL; Rastogi P; Perera S
    Osteoporos Int; 2015 Jun; 26(6):1857-64. PubMed ID: 25792492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.
    Mortensen L; Charles P; Bekker PJ; Digennaro J; Johnston CC
    J Clin Endocrinol Metab; 1998 Feb; 83(2):396-402. PubMed ID: 9467547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S; Delmas P
    Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.